News FDA gives green light to Chiesi's Lamzede Chiesi scores milestone US FDA approval for first AM enzyme replacement therapy, Lamzede.
News FDA starts review of first drug for alpha-mannosidosis, from... The FDA has started a priority review of Chiesi 's velmanase alfa, an enzyme replacement therapy for lysosomal storage disease (LSD) alpha-mannosidosis, with a decision expected in the firs
News UK plan to tackle waiting lists includes NHS App upgrade More community hubs and changes to the NHS App are at the core of the UK government's new elective reform plan.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
